Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratunumab in AL Amyloidosis with Severe Renal Involvement
NCT06571864Completed
- Sponsor
- University of Turin
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of daratumumab in amyloid light chain amyloidosis, sponsored by University of Turin. Primary endpoint: Organ Response Rate at 1 year. Started Jan 2022; status: completed.
02
Drugs
daratumumab
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT06571864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06571864.